RRM2 and cancer: DSS survival contributions of RRM2 in pan-cancer were exhibited in Figure 4A. RRM2 high transcriptional levels were also correlated with bad DSS in 10 types cancers: ACC (HR = 4.55, p < 0.001), BLCA (HR = 1.64, p = 0.007), KIRC (HR = 3.01, p < 0.001), KIRP (HR = 29.70, p < 0.001), LGG (HR = 2.19, p < 0.001), LIHC (HR = 2.04, p = 0.002), LUAD (HR = 1.81, p = 0.002), MESO (HR = 3.73, p < 0.001), PAAD (HR = 1.72, p = 0.022) and UVM (HR = 8.39, p < 0.001).